Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients.

Ahmed O, Littmann K, Gustafsson U, Pramfalk C, Öörni K, Larsson L, Minniti ME, Sahlin S, Camejo G, Parini P, Eriksson M.

J Am Heart Assoc. 2018 Dec 18;7(24):e009876. doi: 10.1161/JAHA.118.009876.

2.

Postprandial Hypertriglyceridemia Is Associated with the Variant 54 Threonine FABP2 Gene.

Garcés Da Silva MF, Guarin YA, Carrero Y, Stekman H, Núñez Bello ML, Hernández C, Apitz R, Fernández-Mestre M, Camejo G.

J Cardiovasc Dev Dis. 2018 Sep 13;5(3). pii: E47. doi: 10.3390/jcdd5030047.

3.
4.

Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR-α modulator for treatment of combined dyslipidemia.

Camejo G.

Atherosclerosis. 2017 Jun;261:163-164. doi: 10.1016/j.atherosclerosis.2017.04.013. Epub 2017 Apr 15. No abstract available.

PMID:
28434555
5.

Selective PPAR modulators (SPPARs) may fill the need for treatment of the atherogenic dyslipidemia of insulin resistance and type 2 diabetes: Can they reduce the associated cardiac risk?

Camejo G.

Atherosclerosis. 2016 Jun;249:224-5. doi: 10.1016/j.atherosclerosis.2016.03.026. Epub 2016 Mar 22. No abstract available.

PMID:
27062491
6.

Macrophages, extracellular matrix, and lipoproteins in arterial cholesterol balance.

Camejo G, Hurt-Camejo E.

J Lipid Res. 2014 Jan;55(1):1-3. doi: 10.1194/jlr.E045732. Epub 2013 Nov 19. No abstract available.

7.

HDL2 interferes with LDL association with arterial proteoglycans: a possible athero-protective effect.

Umaerus M, Rosengren B, Fagerberg B, Hurt-Camejo E, Camejo G.

Atherosclerosis. 2012 Nov;225(1):115-20. doi: 10.1016/j.atherosclerosis.2012.08.040. Epub 2012 Sep 13.

PMID:
22999079
8.

Macrophages exposed to hypoxia secrete proteoglycans for which LDL has higher affinity.

Asplund A, Fridén V, Stillemark-Billton P, Camejo G, Bondjers G.

Atherosclerosis. 2011 Mar;215(1):77-81. doi: 10.1016/j.atherosclerosis.2010.12.017. Epub 2010 Dec 23.

PMID:
21247579
9.

Lysophospholipids: effectors mediating the contribution of dyslipidemia to calcification associated with atherosclerosis.

Camejo G.

Atherosclerosis. 2010 Jul;211(1):36-7. doi: 10.1016/j.atherosclerosis.2010.02.005. Epub 2010 Feb 10. No abstract available.

PMID:
20197191
10.

High plasma phospholipase A2 activity, inflammation markers, and LDL alterations in obesity with or without type 2 diabetes.

Garces F, López F, Niño C, Fernandez A, Chacin L, Hurt-Camejo E, Camejo G, Apitz-Castro R.

Obesity (Silver Spring). 2010 Oct;18(10):2023-9. doi: 10.1038/oby.2010.9. Epub 2010 Feb 4.

11.

Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins.

Davidsson P, Hulthe J, Fagerberg B, Camejo G.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):156-63. doi: 10.1161/ATVBAHA.108.179317. Epub 2009 Sep 24. Review.

PMID:
19778948
12.

Hypoxic regulation of secreted proteoglycans in macrophages.

Asplund A, Stillemark-Billton P, Larsson E, Rydberg EK, Moses J, Hultén LM, Fagerberg B, Camejo G, Bondjers G.

Glycobiology. 2010 Jan;20(1):33-40. doi: 10.1093/glycob/cwp139. Epub 2009 Sep 11.

PMID:
19748976
13.

Hypoxia increases macrophage motility, possibly by decreasing the heparan sulfate proteoglycan biosynthesis.

Asplund A, Ostergren-Lundén G, Camejo G, Stillemark-Billton P, Bondjers G.

J Leukoc Biol. 2009 Aug;86(2):381-8. doi: 10.1189/jlb.0908536. Epub 2009 Apr 28.

PMID:
19401393
14.

In vivo effects of myocardial creatine depletion on left ventricular function morphology and lipid metabolism: study in a mouse model.

Lindbom M, Ramunddal T, Camejo G, Waagstein F, Omerovic E.

J Card Fail. 2008 Mar;14(2):161-6. doi: 10.1016/j.cardfail.2007.10.020.

PMID:
18325464
15.

Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr.

Ståhlman M, Davidsson P, Kanmert I, Rosengren B, Borén J, Fagerberg B, Camejo G.

J Lipid Res. 2008 Feb;49(2):481-90. Epub 2007 Nov 18.

16.

Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans.

Rodriguéz-Lee M, Bondjers G, Camejo G.

Curr Opin Lipidol. 2007 Oct;18(5):546-53. Review.

PMID:
17885426
17.

Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.

Hellmold H, Zhang H, Andersson U, Blomgren B, Holland T, Berg AL, Elebring M, Sjögren N, Bamberg K, Dahl B, Westerberg R, Dillner B, Tugwood J, Tugwood J, Roberts R, Lundholm E, Camejo G, Skånberg I, Evans J.

Toxicol Sci. 2007 Jul;98(1):63-74. Epub 2007 Apr 27.

PMID:
17468185
18.

Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat.

Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR, Oakes ND.

Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1157-65. Epub 2006 Dec 12.

19.

Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis.

Rosengren B, Jönsson-Rylander AC, Peilot H, Camejo G, Hurt-Camejo E.

Biochim Biophys Acta. 2006 Nov;1761(11):1301-8. Epub 2006 Jul 8. Review.

PMID:
17070102
20.

Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.

Zadelaar AS, Boesten LS, Jukema JW, van Vlijmen BJ, Kooistra T, Emeis JJ, Lundholm E, Camejo G, Havekes LM.

Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2560-6. Epub 2006 Aug 24.

PMID:
16931788

Supplemental Content

Loading ...
Support Center